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Licorice (Glycyrrhizae radix) is the roots and stolons of Glycyrrhiza uralensis Fischer or Glycyrrhiza glabra
Linnaeus in the Japanese Pharmacopoeia. Glycyrrhizae radix has been widely used as a sweetener and a
traditional medicine. A Glycyrrhizae radix extract contains many constituents and has antispasmodic,
antitussive, anti-ulcer, and anti-inﬂammatory effects. However, reports comparing the anti-inﬂammatory
effects of these constituents are very few. Here, we puriﬁed several constituents from the roots and
stolons of G. uralensis and examined and compared their anti-inﬂammatory effects by monitoring the
levels of the inﬂammatory mediator, nitric oxide (NO), in interleukin (IL)-1β-treated rat hepatocytes.
From the G. uralensis extract, we puriﬁed the main constituent glycyrrhizin and the constituents that are
characteristic of G. uralensis (chalcones and ﬂavanones). These constituents suppressed NO production in
IL-1β-treated rat hepatocytes, and isoliquiritigenin showed the greatest suppression activity. Iso-
liquiritigenin, isoliquiritin, and liquiritigenin signiﬁcantly decreased both protein and mRNA for the in-
ducible nitric oxide synthase. These constituents reduced the levels of mRNAs encoding tumor necrosis
factor α and IL-6. In contrast, although glycyrrhizin is abundant, it showed a 100-fold lower potency in
NO suppression. Therefore, both glycyrrhizin and the minor constituents (isoliquiritigenin, isoliquiritin,
and liquiritigenin) may be responsible for the anti-inﬂammatory effects of G. uralensis. It is also implied
that these constituents may have a therapeutic potential for inﬂammatory hepatic disorders.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Licorice is as a natural sweetener in foods and a traditional
medicine that is used worldwide to treat a variety of diseases, such
as peptic ulcer and hepatitis [1]. In the Japanese Pharmacopoeia,
licorices are deﬁned as the dried roots and stolons of Glycyrrhiza
uralensis Fischer and Glycyrrhiza glabra Linnaeus and are desig-
nated Glycyrrhizae radix (kanzo in Japanese) [2]. Glycyrrhizae ra-
dix has been used in many formulae of Japanese herbal (Kampo)
medicines, such as kanzoto and shakuyakukanzoto. Glycyrrhizae
radix has a variety of pharmacological properties, including anti-
spasmodic, antitussive, anti-ulcer, and anti-inﬂammatory effects,
and attenuates the adverse effects of other components in the
Kampo formulae [3].
Glycyrrhizae radix includes many constituents: triterpeneB.V. This is an open access article u
shizawa).glycosides (mainly, glycyrrhizin), chalcones (e.g., isoliquiritigenin
and isoliquiritin), and ﬂavanones (e.g., liquiritigenin and liquiritin)
[4,5]. Glycyrrhizin (also designated glycyrrhizic acid) is a glycoside
of glycyrrhetinic acid (also designated glycyrrhetic acid) (Fig. 1A)
and is abundantly present in the roots and stolons. This saponin is
the major sweet constituent and the main bioactive compound in
Glycyrrhizae radix [1], which displays hepatoprotective properties
in humans and mice [6,7]. The contents of isoliquiritin, liquir-
itigenin, and liquiritin in G. uralensis are signiﬁcantly higher than
those of G. glabra; therefore, these constituents are characteristic
of G. uralensis [4,5]. As far as we searched the literatures to date,
there are no reports that compare anti-inﬂammatory activity of
several Glycyrrhizae radix constituents using any types of cells.
The inﬂammatory mediator nitric oxide (NO) plays a pivotal
role in innate immunity and pathophysiology of various diseases,
and inducible nitric oxide synthase (iNOS) synthesizes NO in he-
patocytes and macrophages [8,9]. Similarly in the hepatocytes in
the liver, the iNOS gene is induced by the inﬂammatory cytokinender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Identiﬁcation of the constituents in a G. uralensis water extract. (A) The
chemical structures of the constituents of G. uralensis. GlcA, glucuronic acid. The
C-30 of glycyrrhizin may be conjugated with glucuronic acid in the liver [34].
(B) The fractions of a G. uralensis extract suppress NO induction in rat hepatocytes.
A G. uralensis extract was stepwise fractionated by methanol (0–100%) to give
fractions (GR-0 to 100). The hepatocytes were treated with IL-1β and/or each
fraction for 8 h. The NO levels in the medium (mean7SD) are shown. **Po0.01
versus IL-1β alone.
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this induction mimics liver injury, such as acute hepatitis [9,10]. As
iNOS protein is induced, the NO level linearly increases from 6 h to
12 h after the addition of IL-1β.
Using the hepatocytes, we demonstrated that NO is a sensitive
marker that can be used to monitor inﬂammatory responses to
anti-inﬂammatory drugs [11], Japanese herbal medicines [12] and
their constituents, such as chlorogenic acid (i.e., 5-O-caffeoylquinic
acid) in the ﬂowers and buds of the Japanese honeysuckle (Loni-
cera japonica) [13] and nobiletin (polymethoxylated ﬂavone) in the
peels of Citrus unshiu [14]. Only one paper using primary cultured
hepatocytes, which described anti-inﬂammatory effects of gly-
cyrrhizin, was found in the literatures that we have searched to
date [15]. This report suggested NO suppression activity of gly-
cyrrhizin in primary cultured hepatocytes that were isolated from
Bacillus Calmette-Guérin (BCG)-vaccinated rats. Hepatoprotective
herbal medicines suppress the IL-1β-induced expression of iNOS
and inﬂammatory cytokines, such as tumor necrosis factor α (TNF-
α) and interleukin-6 (IL-6), in hepatocytes [13,14]. The transcrip-
tion factor nuclear factor κB (NF-κB) is involved in these processes
by regulating the expression of iNOS gene and these inﬂammatory
genes [16–18].
iNOS induction is also regulated via a post-transcriptional
mechanism that is mediated by antisense transcripts (asRNAs) [9].
asRNAs are transcribed from the iNOS gene and interact with iNOS
mRNA to stabilize iNOS mRNA [9,19–21]. Recently, herbal con-
stituents (e.g., chlorogenic acid [13], nobiletin [14], gomisin N [18],
and shisoﬂavanone A [22]), as well as Kampo formulae (e.g., in-
chinkoto [12] and ninjinyoeito [23]), have been reported to de-
crease the levels of iNOS asRNA, leading to the inhibition of iNOS
expression.
In the present study, we puriﬁed glycyrrhizin and several
constituents that are characteristic of G. uralensis. Next, we ex-
amined whether the constituents (aglycone–glycoside pairs) sup-
pressed NO production, as well as iNOS gene expression, in IL-1β-
treated hepatocytes. Finally, we investigated which constituent
(s) is responsible for the NO suppression activity of Glycyrrhizae
radix.2. Materials and methods
2.1. Materials
Glycyrrhizin, isoliquiritigenin, and liquiritigenin were pur-
chased from Wako Pure Chemical Industries Ltd. (Osaka, Japan) as
standards. Glycyrrhetinic acid was purchased from Tokyo Chemical
Industry Co., Ltd. (Tokyo, Japan). These compounds (greater than
95% purity) were dissolved in dimethyl sulfoxide.
2.2. Plant materials and extraction
The roots and stolons of G. uralensis Fischer, which were col-
lected from the Inner Mongolia Autonomous Region, China, and
identiﬁed and authenticated by Dr. Yutaka Yamamoto (Tochimoto
Tenkaido Co. Ltd., Osaka, Japan), were purchased from Tochimoto
Tenkaido Co. Ltd. A voucher specimen was deposited in the Rit-
sumeikan Herbarium of Pharmacognosy, Ritsumeikan University,
under the Code number RIN-GU-013. The dried roots and stolons
of G. uralensis (Glycyrrhizae radix; 502.6 g) were pulverized and
extracted by hot water under reﬂux. The solvent was evaporated
under reduced pressure to yield a hot-water extract (160.0 g).
2.3. Isolation of the constituents from a G. uralensis extract
The G. uralensis extract was fractionated on a Diaion HP20
column (Mitsubishi Chemical Corporation, Tokyo, Japan) by the
elution stepwise by methanol–water mixture (0, 20, 40, 60, 80,
and 100% methanol) to give the fractions (GR-0, 20, 40, 60, 80, and
100, respectively). The fraction GR-80 showing high NO suppres-
sion activity was further puriﬁed by Wakogel C-200 chromato-
graphy (Wako Pure Chemical Industries Ltd.) or Cosmosil 75
C18-Prep octadecylsilyl chromatography (Nacalai Tesque, Kyoto,
Japan). Finally, we puriﬁed glycyrrhizin (3850 mg), iso-
liquiritigenin (4.3 mg), isoliquiritin (234 mg), liquiritigenin
(16.4 mg), and liquiritin (8.8 mg). To determine the structures, the
1H- and 13C nuclear magnetic resonance (NMR) spectra, infrared
(IR) spectra, and ultraviolet (UV) spectra were analyzed (Supple-
mentary data).
2.4. Preparation of primary cultured rat hepatocytes
Male Wistar rats were purchased from Charles River Labora-
tories Japan Inc. (Yokohama, Japan), housed at 21–23 °C and ac-
climatized. Hepatocytes were isolated from the rat livers by col-
lagenase perfusion [24]. The isolated cells were resuspended in
Williams’ E (WE) medium (Sigma-Aldrich Corp., St. Louis, MO,
USA), seeded at 1.2106 cells/dish, and incubated at 37 °C for 2 h,
after which the medium was replaced. The hepatocytes were in-
cubated at 37 °C overnight and analyzed the next day. All of the
animal care and experimental procedures were carried out in ac-
cordance with the guidelines and laws of the Japanese government
and were approved by the Animal Care Committee of Ritsumeikan
University, Biwako-Kusatsu Campus.
2.5. Determination of the NO levels and LDH activity
The hepatocytes were each treated with fraction or a con-
stituent in the presence of 1 nM rat IL-1β (PeproTech, Rocky Hill,
NJ, USA) for 8 h. If required, 1400W (Abcam plc., Cambridge,
Cambridgeshire, United Kingdom), a selective iNOS inhibitor [25],
was added to the medium to a ﬁnal concentration of 50 nM. The
levels of nitrite (a stable metabolite of NO) in the medium were
measured using the Griess method [26]. Brieﬂy, 150 μl of the
medium or sodium nitrite (standard) was mixed with 150 μl of the
Griess reagent [0.5% sulfanilamide, 0.05% N-(1-napthyl)
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temperature, absorbance at 540 nmwas measured. To monitor the
cytotoxicity, the LDH activities in the medium were measured
using LDH Cytotoxicity Detection Kits (Takara Bio Inc., Otsu, Shiga,
Japan). Unless cytotoxicity was observed, the half-maximal in-
hibitory concentrations (IC50) were determined [11].
2.6. Measurement of direct NO quenching activity of constituents
Each constituent was added to the WE medium containing
20 μM NaNO2 and incubated at 37 °C for 1.5 h. This medium
(150 μl) was mixed with the Griess reagent (150 μl) and incubated
at room temperature for 5 min. Absorbance at 540 nm was mea-
sured in triplicate to monitor the decrease of nitrite by the con-
stituent. The levels of nitrite using the medium containing NaNO2
alone was set to 100%.
2.7. Western blot analyses
The hepatocytes were treated with 1 nM IL-1β and each con-
stituent for 8 h, and whole-cell lysates were prepared [18]. Brieﬂy,
the hepatocytes were lysed, subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and im-
munoblotted onto a Sequi-Blot membrane (Bio-Rad, Hercules, CA,
USA). Immunostaining was performed using primary antibodies
that were raised against rat iNOS (Thermo Fisher Scientiﬁc, Wal-
tham, MA, USA) and rat β-tubulin (Cell Signaling Technology Inc.,
Danvers, MA, USA), followed by visualization with an Enhanced
Chemiluminescence Blotting Detection Reagent (GE Healthcare
Biosciences Corp., Piscataway, NJ, USA).
2.8. Reverse transcription-polymerase chain reactions (RT-PCR)
The hepatocytes were treated with 1 nM IL-1β and/or each
constituent for 4 h, and the total RNA was prepared [9]. The cDNA
was reverse-transcribed in a strand-speciﬁc manner with an oligo
(dT) primer for mRNAs and a sense primer for iNOS asRNA, and
PCR was performed with paired primers [9]. The primer sequences
CCAACCTGCAGGTCTTCGATG and GTCGATGCACAACTGGGTGAAC
(5′—43′) were used to detect the iNOS mRNA by cDNA ampliﬁ-
cation. The primer sequences that were used for the iNOS
asRNA detection were TGCCCCTCCCCCACATTCTCT (RT), AC-
CAGGAGGCGCCATCCCGCTGC and CAAGGAATTATACACGGAA-
GGGCC (PCR). The primer sequences for PCR were TCCCAA-
CAAGGAGGAGAAGTTCC and GGCAGCCTTGTCCCTTGAAGAGA for
the TNF-α mRNA; GAGAAAAGAGTTGTGCAATGGCA and ATAGG-
CAAATTTCCTGGTTATATCC for the IL-6 mRNA; and TCTGG-
TTGGAATGGTGACAACATGC and CCAGGAAGAGCTTCACTCAAAGCTT
for the elongation factor 1α (EF) mRNA as internal controls. The
mRNA levels were estimated in triplicate by quantitative PCR with
the Thermal Cycler Dice Real Time System (Takara Bio Inc.), and
the obtained values were normalized to EF mRNA [9].
2.9. Statistical analyses
The results that are presented in the ﬁgures are representative
of at least three independent experiments that yielded similar
results. The values are presented as the mean7standard deviation
(SD). The differences were analyzed using Student’s t-test. The
statistical signiﬁcance was set at Po0.05 and Po0.01.3. Results and discussion
3.1. The fractions of a G. uralensis extract suppress the NO inductionin hepatocytes
We extracted the dried roots and stolons of G. uralensis (Gly-
cyrrhizae radix) using hot water, and this extract (GR extract) was
subjected to fractionation by hydrophobicity. Because the high
content of saponins (mostly glycyrrhizin) inhibited phase separa-
tion, the GR extract was not successfully fractionated by the
standard ABC method [13] (data not shown). Therefore, we per-
formed Diaion HP-20 chromatography to fractionate the GR ex-
tract into six fractions.
Then, we investigated the effects of the resultant fractions on
NO induction in IL-1β-treated rat hepatocytes. When each fraction
was simultaneously added to the medium with IL-1β, all of the
fractions signiﬁcantly decreased the levels of NO production
(Fig. 1B). Three fractions GR-60 (21.2 g), GR-80 (22.0 g) and GR-100
(3.7 g), which were eluted with 60%, 80%, and 100% methanol,
respectively, effectively suppressed NO production. The LDH ac-
tivity in the medium was very low (data not shown), suggesting
that all of the fractions of the GR extract were not toxic to hepa-
tocytes at the concentrations that are indicated in the ﬁgure. To-
gether, these data indicate that the three fractions GR-60, GR-80,
and GR-100 may include active compounds that may suppress NO
induction.
3.2. Several constituents in a GR extract suppress NO induction in
hepatocytes
Next, we tried to isolate the constituents that effectively sup-
pressed NO induction from the fractions showing NO suppression
activity. Because the amount of the fraction GR-100 was much
smaller, the fractions GR-60 and GR-80 were subjected to thin
layer chromatography. This analysis showed that the major spots
of both fractions were similarly developed (data not shown).
Therefore, we selected the middle fraction GR-80 and then pur-
iﬁed ﬁve constituents from this fraction, as described in Supple-
mentary data. Finally, we identiﬁed glycyrrhizin and two agly-
cone–glycoside pairs (isoliquiritigenin and isoliquiritin; and li-
quiritigenin and liquiritin) by analyzing the NMR and UV spectra
(Supplementary data). These constituents except for glycyrrhizin
are characteristic of G. uralensis [4,5].
To examine whether the constituents in a GR extract affect iNOS
gene expression, we added each constituent to the medium for
hepatocytes. Among these constituents, isoliquiritigenin sig-
niﬁcantly suppressed NO induction in the presence of IL-1β in a
dose-dependent manner (Fig. 2A). Similarly, isoliquiritin and li-
quiritigenin signiﬁcantly suppressed NO induction. When evalu-
ating the LDH activity in the medium, these constituents displayed
no cytotoxicity at the concentrations that are indicated in Fig. 2A.
When the IC50 values were calculated (Table 1), isoliquiritigenin
showed the highest potency in NO suppression activity, with an
IC50 value of 11.9 μM. In another assay system using a mouse
RAW264.7 macrophage line, an IC50 value of isoliquiritigenin of
7.8 μM was reported [27].
In contrast, the main constituent glycyrrhizin suppressed NO
induction only at a high concentration, showing an IC50 value of
1176 μM, which is approximately 100-fold higher than that of
isoliquiritigenin. Then, we examined the degradation of glycyr-
rhizin by incubating the WE medium containing 1000 μM gly-
cyrrhizin at 37 °C for 8 h. Glycyrrhizin was puriﬁed by Diaion HP-
20 chromatography and analyzed by high-performance liquid
chromatography (HPLC). The content of glycyrrhizin did not
change by the incubation (data not shown). Furthermore, when
the WE medium containing 1000 μM glycyrrhizin was similarly
incubated in the presence of hepatocytes, the content of glycyr-
rhizin was almost the same as that of the medium without in-
cubation (data not shown). These results suggest that the
Fig. 2. The G. uralensis constituents suppress iNOS expression in hepatocytes. (A) The effects of the constituents in a GR extract on the induction of NO production. The
hepatocytes were treated with IL-1β and/or each constituent for 8 h. The NO levels in the mediumwere measured in triplicate (mean7SD). *Po0.05 and **Po0.01 versus IL-
1β alone. ILG, isoliquiritigenin; IL, isoliquiritin; LG, liquiritigenin. (B) The effects of the constituents on the induction of iNOS protein expression. The hepatocytes were treated
with IL-1β and/or each constituent for 8 h. The cell extracts were resolved using SDS-PAGE and immunoblotted with an anti-iNOS or anti-β-tubulin antibody (internal
control). (C) The effects of 1400W, a selective iNOS inhibitor, on the levels of NO (upper panel) and iNOS mRNA (lower panel). The hepatocytes were treated with 50 nM
1400W and/or 100 μM isoliquiritin in the presence of 1 nM IL-1β for 8 h (NO) or 4 h (iNOS mRNA). The NO levels in the mediumwere measured in triplicate (mean7SD). The
total RNA from the cells was analyzed using quantitative RT-PCR to estimate the levels of iNOS mRNA. The mRNA levels were measured in triplicate (mean7SD), the
obtained values were normalized to EF mRNA (internal control), and the value in the presence of IL-1β alone was set at 100%. **Po0.01.
Table 1
The effects of the G. uralensis constituents on NO induction in rat hepatocytes.
Compound Sugar Content [%]a IC50 [μM]b LogPc
Triterpenes:
Glycyrrhetinic acid None ND NA 5.45
Glycyrrhizin Glucuronic acid 3.3771.57 11767482 2.74
Chalcones:
Isoliquiritigenin None 0.05–0.65 11.971.5 3.04
Isoliquiritin Glucose 0.3270.22 40.477.5 0.82
Flavanones:
Liquiritigenin None 0.1170.12 41.275.9 2.79
Liquiritin Glucose 1.6871.06 NA 0.43
ND, not determined; NA, not applicable due to high cytotoxicity (glycyrrhetinic
acid) or low NO suppression activity (liquiritin).
a The contents of isoliquiritigenin (range) [5] and the others (mean7SD;
n¼87) [4] in a G. uralensis extract.
b The half-maximal inhibitory concentration of nitric oxide (NO) production in
hepatocytes (mean7SD; n¼3–5).
c n-Octanol/water partition coefﬁcient as predicted using the ALOGPS 2.1 pro-
gram [29].
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37 °C for 8 h regardless of the presence of hepatocytes, thereby not
affecting its IC50 value.
To investigate whether the constituents in a GR extract had
direct NO quenching activity, assays to measure the NO quenching
were performed, as described in Section 2. We added constituents
to ﬁnal concentrations around their IC50 values (glycyrrhizin,
1000 μM; isoliquiritigenin, 10 μM; isoliquiritin, 40 μM; and li-
quiritigenin, 40 μM) to the medium containing 20 μM NaNO2. The
decreases of NO levels were less than 5% and were statistically not
signiﬁcant (P40.05), comparing with the NO levels of the medium
containing NaNO2 alone. These data suggest that any of these
constituents did not directly quench NO.3.3. The G. uralensis constituents inhibit iNOS gene expression in
hepatocytes
To further investigate the effect of the active G. uralensis con-
stituents on iNOS gene expression, we examined the expression of
the iNOS protein in hepatocytes. As shown in Fig. 2B, western blot
analyses indicated that isoliquiritigenin, isoliquiritin, and liquir-
itigenin decreased the iNOS protein expression that was induced
by IL-1β.
Then, we examined a possibility that these constituents in-
hibited enzyme activity of iNOS protein. Therefore, we added
isoliquiritin and/or 1400W [25], which is a selective iNOS inhibitor
and does not affect the expression of iNOS mRNA, to the medium
and measured the levels of both NO and iNOS mRNA. As shown in
Fig. 2C, the addition of 1400W signiﬁcantly decreased the NO le-
vels, and isoliquiritin also decreased the NO levels, suggesting that
1400W and isoliquiritin showed an additive effect. The addition of
1400W, however, did not decrease in the levels of iNOS mRNA,
whereas isoliquiritin signiﬁcantly reduced the levels of iNOS
mRNA (lower panel). Isoliquiritin also decreased iNOS protein
(Fig. 2B), although isoliquiritin did not inhibit enzyme activity of
iNOS protein (Fig. 2C). Therefore, isoliquiritin may suppress the
iNOS gene expression by reducing the iNOS mRNA, resulting in the
decrease of iNOS protein.
Quantitative RT-PCR analyses revealed that the constituents
including isoliquiritin signiﬁcantly reduced iNOS mRNA levels in a
dose-dependent manner (Fig. 3A), suggesting that these con-
stituents suppressed the induction of iNOS mRNA. Taken together,
isoliquiritigenin, isoliquiritin, and liquiritigenin decreased the le-
vels of both iNOS mRNA and protein. These results indicate that
the three constituents inhibited the IL-1β-induced expression of
the iNOS gene at the transcriptional level.
It is possible that the constituents suppress iNOS expression at
the post-transcriptional level because iNOS asRNA interacts with
Fig. 3. Three constituents reduced the expression of the iNOS gene and inﬂammatory genes. The hepatocytes were treated with IL-1β and/or each constituent for 4 h. The
total RNA from the cells was analyzed using quantitative RT-PCR to estimate the levels of mRNAs or iNOS asRNA. The mRNA levels were measured in triplicate (mean7SD),
the obtained values were normalized to EF mRNA, and the value in the presence of IL-1β alone was set at 100%. The relative levels of iNOS mRNA (A), iNOS asRNA (B), TNF-α
mRNA (C), and IL-6 mRNA (D) are shown. A negative control PCR using total RNA without RT did not give ampliﬁcation (data not shown). ILG, isoliquiritigenin; IL, iso-
liquiritin; LG, liquiritigenin. *Po0.05 and **Po0.01 versus IL-1β alone.
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vels of iNOS asRNA by quantitative RT-PCR. Isoliquiritigenin, iso-
liquiritin, and liquiritigenin signiﬁcantly reduced iNOS asRNA le-
vels (Fig. 3B). Because decreases in iNOS asRNA lead to decreased
iNOS mRNA stability, these results indicate that the three con-
stituents may post-transcriptionally regulate iNOS mRNA levels by
reducing iNOS asRNA stability.
Both transcriptional and post-transcriptional mechanisms to
regulate iNOS expression may be targets of herbal medicines. The
Kampo formula inchinkoto and herbal constituents, such as go-
misin N and nobiletin, affect the nuclear translocation and acti-
vation of NF-κB, leading to the suppression of iNOS gene expres-
sion [12,14,18].
3.4. The G. uralensis constituents suppress inﬂammatory genes
We examined whether the constituents that were isolated from
a G. uralensis extract affect the expression of inﬂammatory genes
in hepatocytes. As shown in Figs. 3C and D, the G. uralensis con-
stituents decreased the levels of the mRNAs encoding TNF-α and
IL-6, whereas the inﬂammatory cytokine IL-1β induced the ex-
pression of these mRNAs. After tissue damage or bacterial infec-
tion, IL-6 is an important mediator of an acute phase response in
the hepatocytes [28]. Because the constituents down-regulated IL-
6 mRNA, these results support that the G. uralensis constituents
may have anti-inﬂammatory effects.
NF-κB is believed to regulate the mRNA expression of these
inﬂammatory genes through the NF-κB-binding site(s) in their
promoters [16,29]. Indeed, liquiritigenin suppressed iNOS expres-
sion by inhibiting NF-κB activation in RAW264.7 macrophages
[30,31]. NF-κB also regulates the transcription of iNOS asRNA [9],
and the G. uralensis constituents decreased the levels of iNOSasRNA (Fig. 3B). Therefore, it is likely that the constituents in a G.
uralensis extract reduce NF-κB activity, resulting in the inhibition
of expression of NF-κB-regulating genes, including not only iNOS
but also inﬂammatory genes in hepatocytes.
3.5. The NO suppression activity of the G. uralensis constituents
We further compared the effects of the aglycone–glycoside
pairs in the G. uralensis constituents. An aglycone of glycyrrhizin is
glycyrrhetinic acid, which is believed to be an active metabolite
[32]. When glycyrrhizin is orally administered, intestinal bacteria
hydrolyze it to glycyrrhetinic acid, which is then absorbed in the
intestine and transferred to the liver [32]. When glycyrrhetinic
acid was added to the medium, it showed toxicity to rat hepato-
cytes (i.e., LDH activity in the medium) at a concentration of more
than 40 μM (data not shown). In contrast, glycyrrhizin did not
display cytotoxicity at 1000 μM (data not shown).
The contents of isoliquiritigenin, isoliquiritin, or liquiritigenin
were much lower than glycyrrhizin [4,5] but displayed high NO
suppression activities, with IC50 values of 11.9–41.2 μM (Table 1).
In contrast, although glycyrrhizin is highly abundant (3.37%) in G.
uralensis, it possessed an IC50 value of 1176 μM in NO suppression.
Together with these data, the NO suppression activity of a GR
extract can be attributed to the activities of both glycyrrhizin and
the three constituents. Because NO is an inﬂammatory mediator,
these constituents may be responsible for the anti-inﬂammatory
effects of G. uralensis.
3.6. Lipophilicity of the G. uralensis constituents
The mechanism how the G. uralensis constituents affect in-
tracellular signal transduction remains unclear. If a constituent is
R. Tanemoto et al. / Biochemistry and Biophysics Reports 2 (2015) 153–159158relatively hydrophobic, the plasma membrane may be permeable
to the constituent. As a marker of lipophilicity (hydrophobicity),
we predicted the n-octanol/water partition coefﬁcient (logP) using
the ALOGPS 2.1 program [33]. The LogP values of the G. uralensis
compounds had IC50 values that ranged from 0.82 to 3.04 (Table 1).
In contrast, glycyrrhetinic acid, which is a hydrolyzed metabolite
of glycyrrhizin and shows toxicity to hepatocytes, had a high logP
value, suggesting that glycyrrhetinic acid may be easily absorbed
by the cell. Glycyrrhetinic acid, which is hydrolyzed from glycyr-
rhizin, is almost completely metabolized through glucuronidation
and/or sulfation in the liver [34]. Therefore, the concentration of
glycyrrhetinic acid in the liver is assumed to be very low; thus,
hepatotoxicity may not appear in vivo. Once a constituent enters
into the cell, it may interact with various proteins, such as protein
kinases. Alternatively, ﬂavonoids from G. uralensis may bind to
mRNA or asRNA because ﬂavonoids (i.e., catechins and apigenin)
bind to RNA [35,36]. It is possible that these intracellular interac-
tions may affect gene expression.
3.7. The potential use of the G. uralensis constituents for an anti-
inﬂammatory therapy
We compared the NO suppression potency of the G. uralensis
constituents with that of other herbal constituents in hepatocytes.
The IC50 value of isoliquiritigenin was much lower than that of
nobiletin (51 μM) [14], suggesting that isoliquiritigenin has high
potency in NO suppression. Furthermore, isoliquiritigenin, iso-
liquiritin, and liquiritigenin decreased the mRNA levels of in-
ﬂammatory cytokines, including TNF-α and IL-6 (Fig. 3C, D). In
contrast, an IC50 value of glycyrrhizin was higher than that of
chlorogenic acid (652 μM) [13]. Although abundant glycyrrhizin
showed much lower potency in NO suppression in hepatocytes
(Table 1), its hepatoprotective activities have been reported [6,7].
Taken together, the anti-inﬂammatory activity of G. uralensis in
hepatocytes may be attributed to the activities of not only gly-
cyrrhizin but also the three constituents. Each constituent may be
differentially responsible for a variety of pharmacological effects of
G. uralensis.
The G. uralensis constituents have potential values to treat in-
ﬂammatory diseases, especially viral hepatitis, alcoholic liver dis-
eases, and non-alcoholic steatohepatitis (NASH). Similarly to her-
bal medicines for prostate cancer [37], future clinical trials are
required to examine whether the G. uralensis constituents are used
as a complementary and alternative medicine for an anti-in-
ﬂammatory therapy for inﬂammatory hepatic disorders.Acknowledgments
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